Generation Bio to Present at the Canaccord Genuity 44th Annual Growth Conference
Generation Bio Co. (Nasdaq: GBIO), a biotechnology company focused on developing genetic medicines for rare and prevalent diseases, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's president and CEO, Geoff McDonough, M.D., will engage in a fireside chat on Tuesday, August 13th, 2024, at 2:30 p.m. ET in Boston.
Investors and interested parties can access a live webcast of the presentation through the investor section of Generation Bio's website at investors.generationbio.com. For those unable to attend the live event, a replay will be available on the same platform for 30 days following the conference.
Generation Bio Co. (Nasdaq: GBIO), un'azienda biotecnologica incentrata sullo sviluppo di terapie genetiche per malattie rare e diffuse, ha annunciato la sua partecipazione alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity. Il presidente e CEO dell'azienda, Geoff McDonough, M.D., parteciperà a una chiacchierata informale martedì 13 agosto 2024, alle 14:30 ET a Boston.
Gli investitori e le parti interessate possono accedere a un webcast in diretta della presentazione tramite la sezione investitori del sito di Generation Bio su investors.generationbio.com. Per coloro che non possono partecipare all'evento dal vivo, una registrazione sarà disponibile sulla stessa piattaforma per 30 giorni dopo la conferenza.
Generation Bio Co. (Nasdaq: GBIO), una empresa de biotecnología enfocada en el desarrollo de terapias genéticas para enfermedades raras y prevalentes, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. El presidente y CEO de la empresa, Geoff McDonough, M.D., participará en una charla informal el martes 13 de agosto de 2024, a las 2:30 p.m. ET en Boston.
Los inversores y partes interesadas pueden acceder a un webcast en vivo de la presentación a través de la sección para inversores del sitio web de Generation Bio en investors.generationbio.com. Para aquellos que no puedan asistir al evento en vivo, habrá una repetición disponible en la misma plataforma durante 30 días después de la conferencia.
Generation Bio Co. (Nasdaq: GBIO)는 희귀 및 유행 질병을 위한 유전자 치료제를 개발하는 데 중점을 둔 생명공학 회사로, Canaccord Genuity 제44회 연례 성장 컨퍼런스에 참가한다고 발표했습니다. 회사의 회장이자 CEO인 Geoff McDonough, M.D.는 2024년 8월 13일 화요일 오후 2시 30분 ET에 보스턴에서 진행되는 대담에 참여합니다.
투자자 및 관심 있는 분들은 Generation Bio 웹사이트의 투자자 섹션을 통해 프레젠테이션의 실시간 웹캐스트에 접근할 수 있습니다: investors.generationbio.com. 현장에 참석할 수 없는 분들을 위해 동일한 플랫폼에서 컨퍼런스 후 30일간 재생이 가능합니다.
Generation Bio Co. (Nasdaq: GBIO), une entreprise biotechnologique axée sur le développement de thérapies géniques pour des maladies rares et courantes, a annoncé sa participation à la 44ème Conférence Annuelle de Croissance de Canaccord Genuity. Le président et PDG de l'entreprise, Geoff McDonough, M.D., participera à une discussion informelle le mardi 13 août 2024, à 14h30 ET à Boston.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section investisseurs du site de Generation Bio à investors.generationbio.com. Pour ceux qui ne peuvent pas assister à l'événement en direct, un replay sera disponible sur la même plateforme pendant 30 jours après la conférence.
Generation Bio Co. (Nasdaq: GBIO), ein Biotechnologieunternehmen, das sich auf die Entwicklung genetischer Therapien für seltene und verbreitete Krankheiten spezialisiert hat, hat seine Teilnahme an der 44. jährlichen Wachstums-Konferenz von Canaccord Genuity bekannt gegeben. Der Präsident und CEO des Unternehmens, Geoff McDonough, M.D., wird am Dienstag, den 13. August 2024, um 14:30 Uhr ET in Boston an einem informellen Gespräch teilnehmen.
Investoren und Interessierte können über den Investorenteil der Website von Generation Bio unter investors.generationbio.com auf einen Live-Webcast der Präsentation zugreifen. Für diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, wird auf derselben Plattform eine Wiederholung für 30 Tage nach der Konferenz verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13th, 2024 at 2:30 p.m. ET in Boston.
A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With these platforms, Generation Bio aims to develop the next wave of non-viral genetic medicines to support its mission to extend the reach of genetic medicine to more people living with more diseases, around the world.
For more information, please visit www.generationbio.com.
Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638
FAQ
When is Generation Bio (GBIO) presenting at the Canaccord Genuity Growth Conference?
Who will be representing Generation Bio (GBIO) at the Canaccord Genuity conference?
How can I watch Generation Bio's (GBIO) presentation at the Canaccord Genuity conference?
For how long will the replay of Generation Bio's (GBIO) presentation be available?
